Globenewswire·2026-03-12 12:45Core Viewpoint - NEXGEL, Inc. has announced a significant transaction to license and acquire a portfolio of regenerative biomaterial products from Celularity Inc., which is expected to triple its annual revenue and make the company immediately profitable upon closing [1][2]. Financial Considerations - The transaction includes a $15 million upfront cash payment and potential milestone payments of up to $20 million based on net sales targets related to the portfolio [1][5]. - This deal is anticipated to significantly enhance NEXGEL's revenue base, projecting annual revenue to reach approximately $35 million [1][2]. Product Portfolio - The acquired portfolio consists of six established regenerative biomaterial products focused on tendon repair, skin grafts, and bone growth, all of which have over a decade of clinical use and existing insurance reimbursement pathways [3]. - The transaction is expected to bring an experienced commercial and scientific team to NEXGEL, thereby expanding the company's capabilities in the medical technology sector [3]. Company Background - NEXGEL is a provider of healthcare, beauty, and over-the-counter products, specializing in ultra-gentle, high-water-content hydrogel products for various applications [6]. - The company has been developing and manufacturing electron-beam, cross-linked hydrogels for over two decades and has established brands such as SilverSeal and Hexagels [6].